Letech Biotechnology Consulting

Laticon Biopharma (also known as Letech Biotech) is a biotechnology company founded in Suzhou, China, in November 2020 by a team of senior scientists returning from the United States. The company focuses on the discovery and development of innovative biomacromolecule drugs for tumor immunotherapy and autoimmune diseases. Utilizing its proprietary complementary bispecific antibody technology and immune granulocyte redirecting dual antibody technology, Laticon aims to create therapies with enhanced safety and clinical efficacy. The company has successfully completed proof-of-concept for six first-in-class (FIC) projects and is advancing multiple candidates toward clinical development.